BeiGene Ltd Stock News

The Chinese pharmaceutical company saw a bounce back after positive news from government officials.

The Chinese pharmaceutical company saw a bounce back after positive news from government officials.

BeiGene (BGNE) and its partner Medison Pharma Ltd. announced on Tuesday that Israel approved its tyrosine kinase inhibitor Brukinsa for adults with Waldenström’s Macroglobulinemia ((WM)),…

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week. Kala Pharmaceuticals, Inc. (NASDAQ: KALA ) was among the biggest gainers of the week. The stock moved out of penny stock territory after the company announced UnitedHealth Incorporated (NYSE: UNH ) added Eysuvis 0.25% as a covered brand on its commercial formularies, effective March 2022. China-based biopharma companies Zai Lab Ltd. (NASDAQ: ZLAB ), BeiGene Ltd. (NASDAQ: BGNE ) and Hutchmed China Ltd (NASDAQ: HCM ) came under selling pressure after the SEC included these companies in the list of companies facing delisting threat. Here are the key catalysts that could move stocks in the unfolding week: Conferences World Sleep Congress, or WSC, 2022: March 11-16, in Rome, Italy Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (hybrid event): March 13-16 Roth 34th Annual Healthcare Conference: March 14 Oppenheimer Virtual Annual Healthcare Conference: March 15-16 Barclays Global Healthcare Conference: March 15-17, in Miami, Florida AD/PD 2022: International Conference On Alzheimer''s And Parkinson''s Diseases And Related Neurological Disorders: March 15-22, in Barcelona, Spain 1st Annual Needham Virtual Neuroscience Forum: March 16 Guggenheim Virtual Healthcare Talks - Targeted Protein Degradation Day: March 16 American Society for Clinical Pharmacology & Therapeutics, ASCPT, Annual Meeting: March 16-18 Society of American Gastrointestinal And Endoscopic Surgeons, or SAGES, 2022 Annual Meeting: March 16-19, in Denver, Colorado American Pain Society, or APS, Annual Scientific Meeting: March 17-20, in Scottsdale, Arizona Society of Gynecologic Oncology, or SGO, Annual Meeting on Women''s Cancer: March 19-22, in Phoenix, Arizona European Group for Blood and Marrow Transplantation, or EBMT, Annual Congress: March 19-23, in Prague, Czech Republic PDUFA Dates The Food and Drug …

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB ), BeiGene Ltd (NASDAQ: BGNE ), and Hutchmed China Ltd (NASDAQ: HCM ), have been flagged by the SEC for failing to comply with a law governing US-listed companies. In statements responding to the SEC''s provisional list, all three companies suggest they expect more companies to come under regulatory scrutiny as they file their annual reports. The law causing panic is the Holding Foreign Companies Accountable Act (HFCAA). It requires the SEC to identify public companies whose auditing firms cannot be reviewed or inspected by the nonprofit Public Company Accounting Oversight Board (PCAOB) due to … Full story available on Benzinga.com

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. The post Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR,

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM), have been flagged by the SEC for failing to

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In Europe Valneva SE (NASDAQ: VALN ) received a small set of additional questions from the European Medicines Agency''s Committee for Medicinal Products for Human Use regarding the regulatory review of its inactivated, COVID-19 vaccine candidate, VLA2001. Earlier in late February, the company received the first set of questions from the CHMP , to which it responded within two working days. The company said it has received a tentative timetable from the EMA. Valneva also anticipates receiving a positive CHMP recommendation for conditional approval of VLA2001 in April and subsequently it expects to start delivering planned doses of VLA2001 to European countries in the second quarter of 2022. The stock was up 4.61% to $34.02 in premarket trading. Click here to access Benzinga''s FDA Calendar Emergent BioSolutions Begins Phase 1 …

BeiGene (BGNE) said the China National Medical Products Administration ((NMPA)) granted conditional approval to tislelizumab to treat adult patients with advanced unresectable…

During the recent session, BeiGene Ltd. (NASDAQ:BGNE)’s traded shares were 0.59 million, with the beta value of the company hitting 0.81. At the last check today, the stock’s price was $166.60, reflecting an intraday loss of -14.77% or -$28.87. The 52-week high for the BGNE share is $426.56, that puts it down -156.04 from that … BeiGene Ltd. (NASDAQ: BGNE): Is It Possible To Be Down -27.85% YTD And Still Lose Money Read More »

Shares of Chinese pharmas Zai Lab (ZLAB) and Beigene (BGNE) are down significantly amid allegations they are in violation of a lw preventing ownership by foreign governments.

Regulators started a two-year clock Thursday to force China-based companies to comply with U.S. trading rules — leading three biotech stocks to crumble.

Shares of many U.S.-listed Chinese stocks tumbled Thursday after the Securities and Exchange Commission put out an update about foreign companies using accounting firms or branches that cannot be adeq

BeiGene (BGNE) medicine Brukinsa was approved by Health Canada to treat adult patients with marginal zone lymphoma ((MZL)) who have received at least one prior anti-CD20-based…